🔖
Cite This Article
İNCE, A. T. (2014). Do we have to worry for thrombocytopenia during treatment of hepatitis C. Turkish Journal of Gastroenterology, Cilt: 25 - Sayı: 3, 344–345. https://ajindex.com/articles/410279
Journals / Turkish Journal of Gastroenterology / 2014 / Cilt: 25 - Sayı: 3
Do we have to worry for thrombocytopenia during treatment of hepatitis C
- Pages
- 344–345
- DOI
- —
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗References (2)
- Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: A systematic review. J Viral Hepat 2011; 18: 1-7. [CrossRef] Schmid M, Kreil A, Jessner W, et al. Suppression of haematopoi- esis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005; 54: 1014-20. [CrossRef] Pegasys (peginterferon alfa-2a). Full prescribing information. South San Francisco: USA; 2011.
- McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36. [CrossRef] Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increas- es platelet numbers in thrombocytopenic patients with HCV in- fection and cirrhosis, allowing for effective antiviral therapy. Gas- troenterology 2014; 146: 442-52. [CrossRef]